Chellampillai Bothiraja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chellampillai Bothiraja has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Atmaram Pawar
Bharati Vidyapeeth Deemed Univ BVDU, Poona Coll Pharm, Dept Pharmaceut, Pune 411038, Maharashtra, India
12 shared publications- Karimunnisa Sameer Shaikh
Department of Pharmaceutics, Progressive Education Society’s Modern College of Pharmacy, Savitribai Phule Pune University, Pune, India
7 shared publications - Piyush Pradeep Mehta
Global Respiratory R&D, Cipla R&D Center
6 shared publications Ashwin Mali
3 shared publicationsRavindra Kamble
Department of Pharmaceutics, Bharati Vidyapeeth (Deemed to be University) (BVDU), Poona College of Pharmacy, Pune, India
3 shared publicationsS. Rajalakshmi
B Department of Pharmaceutics , Dr D. Y. Patil College of Pharmacy , Pune , India
3 shared publications
Latest Publications
- Open Access
- 9 August 2024
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (4) , 687-702
Investigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: In vitro and in vivo pharmacokinetic study
Background and purpose: Sorafenib tosylate (SFN), a potent multikinase inhibitor, is used for the treatment of various cancers. However, it shows limited therapeutic applications due to its poor biopharmaceutical properties. The aim of the present investigation is to develop surface solid dispersion (SSD) of SFN using adsorbent to improve its solubility, bioavailability and therapeutic efficacy. Experimental approach: The SFN-SSD was prepared by modified solvent evaporation technique using Neusilin US2 (magnesium aluminometasilicate) as an adsorbent and sodium dodecyl sulphate as a surfactant. SFN-SSD was optimized by adopting the design of experiment (DOE) using 32 factorial designs and characterized in terms of in-vitro and in-vivo efficacy. Key results: The obtained SFN-SSD showed more than 20-fold improvement in SFN solubility. The FTIR depicted hydrogen bonding between SFN and Neusilin. Further, PXRD and DSC indicated the molecular dispersion of SFN to be amorphous. SFN-SSD and SFN immediate release tablets reflected cumulative release of 97.13 and 29.93 % in 1 h. The pharmacokinetics study of SFN-SSD showed 2 and 6.5-fold improvement in maximum concentration (Cmax,) and area under the curve (AUC0-t) as compared to pure SFN due to faster drug release at the absorption site. Conclusion: The study concluded that the SSD could be a scalable formulation approach and more industry-friendly technology to improve the biopharmaceutical properties of SFN.
- 9 August 2024
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 12 (4) , 687-702
Open AccessInvestigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: In vitro and in vivo pharmacokinetic study
Background and purpose: Sorafenib tosylate (SFN), a potent multikinase inhibitor, is used for the treatment of various cancers. However, it shows limited therapeutic applications due to its poor biopharmaceutical properties. The aim of the present investigation is to develop surface solid dispersion (SSD) of SFN using adsorbent to improve its solubility, bioavailability and therapeutic efficacy. Experimental approach: The SFN-SSD was prepared by modified solvent evaporation technique using Neusilin US2 (magnesium aluminometasilicate) as an adsorbent and sodium dodecyl sulphate as a surfactant. SFN-SSD was optimized by adopting the design of experiment (DOE) using 32 factorial designs and characterized in terms of in-vitro and in-vivo efficacy. Key results: The obtained SFN-SSD showed more than 20-fold improvement in SFN solubility. The FTIR depicted hydrogen bonding between SFN and Neusilin. Further, PXRD and DSC indicated the molecular dispersion of SFN to be amorphous. SFN-SSD and SFN immediate release tablets reflected cumulative release of 97.13 and 29.93 % in 1 h. The pharmacokinetics study of SFN-SSD showed 2 and 6.5-fold improvement in maximum concentration (Cmax,) and area under the curve (AUC0-t) as compared to pure SFN due to faster drug release at the absorption site. Conclusion: The study concluded that the SSD could be a scalable formulation approach and more industry-friendly technology to improve the biopharmaceutical properties of SFN.
- Open Access
- 5 June 2024
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 1 (4) , 765-774
Biopharmaceutical advancement of efonidipine hydrochloride ethanolate through amorphous solid dispersion of a Parteck SLC mesoporous silica polymer
Parteck® SLC mesoporous silica based amorphous solid dispersion improved solubility, bioavailability of efonidipine hydrochloride ethanolate.
- 5 June 2024
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 1 (4) , 765-774
Open AccessBiopharmaceutical advancement of efonidipine hydrochloride ethanolate through amorphous solid dispersion of a Parteck SLC mesoporous silica polymer
Parteck® SLC mesoporous silica based amorphous solid dispersion improved solubility, bioavailability of efonidipine hydrochloride ethanolate.
- 4 March 2023
- Published by Taylor & Francis in Analytical Chemistry Letters
- Vol. 13 (2) , 202-212
Investigation of a Quantitative Bioanalytical HPLC Method for the Assessment of Famotidine in Pre-clinical Samples: Application for Pharmacokinetic Studies
- 4 March 2023
- Published by Taylor & Francis in Analytical Chemistry Letters
- Vol. 13 (2) , 202-212
Investigation of a Quantitative Bioanalytical HPLC Method for the Assessment of Famotidine in Pre-clinical Samples: Application for Pharmacokinetic Studies
- Open Access
- 14 July 2020
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 1 (6) , 1763-1774
Advanced development of a non-ionic surfactant and cholesterol material based niosomal gel formulation for the topical delivery of anti-acne drugs
The aim of the present investigation was to develop adapalene (ADP), a high lipophilicity and low solubility anti-acne drug-loaded niosomal topical gel formulation, in order to improve its therapeutic efficacy.
- 14 July 2020
- Published by Royal Society of Chemistry (RSC) in Materials Advances
- Vol. 1 (6) , 1763-1774
Open AccessAdvanced development of a non-ionic surfactant and cholesterol material based niosomal gel formulation for the topical delivery of anti-acne drugs
The aim of the present investigation was to develop adapalene (ADP), a high lipophilicity and low solubility anti-acne drug-loaded niosomal topical gel formulation, in order to improve its therapeutic efficacy.
- 13 February 2020
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 44 (11) , 4346-4352
Development and validation of a bioanalytical HPLC method for simultaneous estimation of cinnamaldehyde and cinnamic acid in rat plasma: application for pharmacokinetic studies
A rapid, sensitive and accessible HPLC-UV method was developed and validated for simultaneous detection of CNAD and CA up to 1.0 ng ml−1 in plasma samples.
- 13 February 2020
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 44 (11) , 4346-4352
Development and validation of a bioanalytical HPLC method for simultaneous estimation of cinnamaldehyde and cinnamic acid in rat plasma: application for pharmacokinetic studies
A rapid, sensitive and accessible HPLC-UV method was developed and validated for simultaneous detection of CNAD and CA up to 1.0 ng ml−1 in plasma samples.